TR202002326A2 - Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-5 - Google Patents
Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-5Info
- Publication number
- TR202002326A2 TR202002326A2 TR2020/02326A TR202002326A TR202002326A2 TR 202002326 A2 TR202002326 A2 TR 202002326A2 TR 2020/02326 A TR2020/02326 A TR 2020/02326A TR 202002326 A TR202002326 A TR 202002326A TR 202002326 A2 TR202002326 A2 TR 202002326A2
- Authority
- TR
- Turkey
- Prior art keywords
- agents
- compound
- formula
- mdm2
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 8
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract description 26
- 101100236865 Mus musculus Mdm2 gene Proteins 0.000 title description 23
- 101150024228 mdm2 gene Proteins 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 12
- 230000003993 interaction Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 230000001028 anti-proliverative effect Effects 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 230000003474 anti-emetic effect Effects 0.000 claims description 3
- 239000002111 antiemetic agent Substances 0.000 claims description 3
- 229940125683 antiemetic agent Drugs 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 229940043355 kinase inhibitor Drugs 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000002758 colorectal adenoma Diseases 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229940127096 cytoskeletal disruptor Drugs 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 31
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 27
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- -1 chlortheophyllonate Chemical compound 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 101001004932 Pinus strobus Putative lactoylglutathione lyase Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000001117 malignant triton tumor Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000012819 MDM2-Inhibitor Substances 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical group C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000005623 oxindoles Chemical class 0.000 description 2
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Chemical class 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- BDUHCSBCVGXTJM-WUFINQPMSA-N 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone Chemical class CC(C)OC1=CC(OC)=CC=C1C1=N[C@@H](C=2C=CC(Cl)=CC=2)[C@@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-WUFINQPMSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010004433 Benign ovarian tumour Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003795 iobenguane (123i) Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000000436 ligase inhibitor Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940005619 omacetaxine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229940118537 p53 inhibitor Drugs 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Buluş yeni bir MDM2 aktivitesi inhibitörü olarak kullanım için formül I ile gösterilen bileşik veya bunun farmasötik olarak kabul edilebilir bir türevi ile ilgilidir
Description
TARIFNAME
YENI MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITÖRÜ
OLARAK KULLANMAK IÇIN DRG-MDMZ-S
Teknik Dayanak
PS3, hücre döngüsünü koruyan ve tümör baskilayici islevini üstlenen önemli bir
gendir. Hücresel fonksiyonlarin, DNA onariminin, nörodejeneratif hastaliklarin,
yaslanmanin, iskeminin, apoptozun ve hücre siklüsü durdurulmasinin düzenlenmesi
konularinda önemli islevlere sahiptir. Bu p53 aktivitelerinin bir çogu, onkojenik
hasari önleyerek, onkojenik ilerleyici hücreleri onararak veya ortadan kaldirarak
tümörün baskilanmasinda rol oynamaktadir. PS3 islevlerinin kaybi, çesitli organlarda
kanser gelisimi ile iliskilendirilmektedir. Metabolik stres ve onkojenlerin artmasi
durumunda, p53 seviyeleri de artmaktadir. P53 seviyelerinde meydana gelen optimum
artislar hayati önem tasimaktadir. Bununla birlikte, p53 seviyesinin asiri veya yetersiz
olmasi, genin hatali çalistiginin açik bir isaretidir. Asiri olmasi apoptoza neden
olurken, yetersiz olmasi tümör olusumuna yol açar. P53'ün dogal negatif regülatörü,
bir endojen p53 inhibitörü olan Mouse Double Minute 2'dir (MDM2). MDM2 geni,
p53'ün p53 ubikuitinasyonu ile transkripsiyonel aktivasyonunu negatif olarak
düzenleyen bir proto-onkojendir. Bu düzenleme, normal hücre döngüsü ilerlemesini
ve hücre sagkalimini koruyarak, düsük p53 seviyeleri saglamak açisindan çok
önemlidir. Bu nedenle, en yaygin p53 baskilama mekanizmasi MDMZ'yi
içermektedir.
PS3, normal hücrelerde stres olmadan 5-30 dakikalik yarilanma ömrüne sahip kararsiz
bir proteindir. Çekirdek ve sitoplazmada proteazomlar tarafindan parçalanmak üzere
MDM2 tarafindan sürekli olarak mono-bikitize edilmektedir. MDM2 çekirdekte
normal hücresel kosullar altinda eksprese edilmektedir; ancak sitoplazmada yer
degistirebilir ve p53 gibi bazi hedeflerin proteazomlari ile parçalanmaya katki
saglayabilmektedir. Hücresel stres olmasi halinde p53 yolu aktive edilir ve onkojenik
potansiyelli hücrelerin proliferasyonunu inhibe ederek, tümör hücresi inhibisyonu
meydana gelir. PS3 yolu, endojen negatif regülatörlerin (özellikle MDM2) daha fazla
okunmasindan dolayi etkisiz hale getirilmektedir. Tümörlerin %17'sinden fazlasi
kemoterapötiklerde kötü prognoza ve tedavi basarisizligina yol açan MDM2 gen
amplifikasyonu mevcut oldugunu göstermektedir.
P53-MDM2 etkilesiminin önemi, in Viva deneylerle gösterilmistir. Insan
sarkomlarinda MDM2 amplifikasyonu gözlenmistir. MDM2`nin p53 inhibisyon
etkisini tersine çevirmek (antagonize etmek) için çesitli yaklasimlar kullanilmistir. Bu
yöntemler, p53-MDM2 etkilesimlerini önleyen MDM2 antagonistlerinin
gelistirilmesini de kapsamaktadir. Dolayisiyla, MDMZ'nin dogrudan inhibisyonu,
MDMZ'nin hem p53-bagimli hem de p53-bag1msiz islevlerini inhibe edebildiginden
inhibitör ve terapötik aktivitelere neden olabilir. MDM2 düzeyleri yumurtalik
kanserlerinde artmaktadir; iyi huylu yumurtalik tümörlerinde ve normal
yumurtaliklarda ise çok düsüktür. Asiri okunan MDM2, p53'ün N-terminal alanina
dogrudan baglanir ve asagidaki mekanizmalardan biriyle inhibe olarak: (i) E3 ubikitin
ligazi olarak hareket ederek nükleer ve sitoplazmik 268 protizomlari içerisinde
ubikitine bagimli p53 degradasyonunu uyarir; (ii) p53'ün çekirdekten sitoplazmaya
tasinmasini saglayarak, p53'ün transkripsiyonel yeteneginin azaltilmasini saglar; (iii)
p53 ile kuvvetli etkilesime girerek DNA'ya baglanma yetenegini azaltir ve p53'ü
transkripsiyonel olarak islevsiz hale getirir. P53 mutasyonlari ve delesyonlari ve/veya
MDM2 amplifikasyonu ve asiri ekspresyonu dahil olmak üzere p53-MDM2 yolunun
düzensizligi, çesitli insan kanserlerinde en sik gözlenen moleküler degisiklik
niteligindedir. p53-MDM2 denge bozulmasi normal hücrelerin habis
transformasyonuna yol açabilir ve ayrica tümör hücrelerinin kemosensitivitesini
etkileyebilir. MDM2 asiri ekspresyonu, p53'ün apoptotik islevlerinin baskilanmasina
ve dolayisiyla kanser hücrelerinin kontrolsüz bir sekilde çogalmasina yol açar.
MDM2 proteini, p53'ün bagli oldugu N-terminal alani (nükleer lokalizasyon sekansi
(NLS), nükleer çikis sekansi (NES), Box-l alani) dahil olmak üzere dört fonksiyonel
bagimsiz alandan meydana gelmektedir (aa 19-102), merkezi asidik alan (aa 223-
Teknigin Bilinen Durumu
Küçük moleküllerle p53-MDM2 etkilesimlerinin engellenmesi siddetle tavsiye
edilmektedir ve son yillarda çok sayida MDM2 inhibitörü kesfedilmistir. P53-MDM2
kompleksinin yapisal özellikleri, p53-MDM2 etkilesimlerini önlemek için anahtar
kalintilarini taklit eden küçük moleküllerin tasarimina yol açmaktadir. Kanser
hücrelerinde apoptozu indükleyebilen ve p53-MDM2 etkilesimini bozan ve p53
fonksiyonlarini geri yükleyebilen nutlin bilesikleri, bilinen en iyi MDM2 antagonistleri
olarak nitelendirilmektedir.
Nutlinler, vahsi tip p53 hücrelerindeki antitümör profilleri için iyi bilinen bilesiklerdir.
P53-MDM2 etkilesiminin inhibisyonu için seçici nutlinler, küçük moleküllerin es
yönlü bir imidazolin sinifidir. Nutlin türevi MI-219 (oksindol halkasi içermektedir),
p53-MDM2 etkilesimlerini inhibe ederek kanser hücrelerinde in vitro ve in
vivo apoptozunu indüklemektedir. Ml-219'un, vahsi tip p53 içeren akciger kanseri
hücrelerinin büyümesini, Gl veya G2 fazinda hücre döngüsü durdurmasi ile seçici bir
sekilde inhibe ettigi gösterilmistir. Ml-219 ve bir oksindol türevi (Ml-319) olan
nutlin-3a analogu, MDM2 proteinini, dogal bir p53 peptidinden 500 kat daha yüksek
baglanma afinitesiyle baglayan sentetik ve küçük bir moleküldür. Çalismalar, MI-
319'un kemoterapötik ilaç Cisplatin ile kombinasyon halinde hücre döngüsü
büyümesini sinerjik olarak baskiladigini ve pankreas kanseri hücre hatlarinda
apoptozu indükledigini göstermistir. 7-nitr0-5-deazaIlaVin ve deazatlavin-S,
MDM2'nin otoikuitini yapan güçlü MDM2 E3 ligaz inhibitörleridir. Oksindol ve indol
bilesiklerinin tibbi öneminden dolayi bu bilesiklerin kanser hücre hatlarina karsi
sitotoksik aktiviteye sahip türevleri bildirilmistir. Spirotetrahidrotiyopiran oksindol
iskelesi, p53-MDM2'nin bir inhibitörü olarak olusturulmustur ve MDM2 inhibitörü ve
antitümör aktivitesi olarak iyi bir kuvvet göstermistir. Insan akciger kanseri hücresi
A549, insan karaciger kanseri hücresi BEL7402 ve insan kolon kanseri hücresi HCT-
S'e karsi spirosiklik oksindol iskeletinin antitümör aktivitesi arastirilmistir. Indol
türevlerinin güçlü oldugu ve farkli kanser türlerine karsi yüksek terapötik aktiviteye
sahip oldugu gösterilmistir. Halen kullanilan FDA onayli kemoterapötiklerden
bazilari, antitümör aktiviteleri klinik asamada degerlendirilen indol halkalari
içermektedir.
PS3 ve MDM2 etkilesimi ile etkilesen bazi moleküller olmasina ragmen, p53'ün
kontrolsüz tümör büyümesine karsi faydali etki gösterebilmesi için MDM2 inhibitörleri
olarak islev görebilen daha iyi farmakokinetik profillere sahip yeni ilaçlara halen
ihtiyaç duyulmaktadir.
Mucitler, formül I ile gösterilen yeni bilesigin, p53-MDM2 etkilesiminin bir
inhibitörü olarak islev gördügünü tespit etmistir.
Dolayisiyla, bu bulusa göre formül I ile gösterilen bilesik, p53-MDM2 yolunun bir
etkilesiminin rol oynadigi çesitli bozukluklarda kullanima müsait yeni bir bilesigin
temsilcisidir. Bu tür hastaliklar, örnegin kanser gibi proliferatif hastaliklar olabilir. Bu
nedenle, mevcut bulus sadece formül I ile gösterilen yeni bilesiklerle degil, ayni
zamanda bahsedilen bilesiklerin kanser gibi proliferatif hastaliklarin tedavisinde
kullanimiyla da ilgilidir.
Bulusun Ayrintili Açiklamasi
Bulus, DRG-MDM2-5 olan formül I ile gösterilen bilesik veya bunun farmasötik
olarak kabul edilebilir bir türevi ile ilgilidir.
Formül I
Aksi belirtilmedikçe, "mevcut bulusa ait bilesik" veya "bulusa ait bilesik" veya
yerine kullanilabilir ve formül I'e ait bilesikler ve bunlarin tuzlari, `hidrat1ar veya
formül I bilesiginin veya tuzlarinin solvatlari, tüm stereoizomerler (diastereomerler ve
enantiyomerler), totomerler, izotopik olarak etiketlenmis bilesikler (döteryum
sübstitüsyonlari dahil) veya insan vücudunun fizyolojik kosullari altinda olusan
formlarin yani sira dogal olarak olusanlar (örnegin polimorflar, solvatlar ve/veya
hidratlar) anlamina gelecektir.
Yani, "farmasötik olarak kabul edilebilir türev" terimi, hidratlari, solvatlari, ön
ilaçlari, tüm stereoizomerleri, tuzlari, esterleri, totomerleri, izotopik olarak
etiketlenmis türevleri veya insan vücudunun fizyolojik kosullari altinda olusan formül
formül I'e ait bilesigin karboksilat anyon formu).
Formül [0
Bulusun çesitli düzenlemeleri burada tarif` edilmektedir. Belirtilen her bir
düzenlemenin, baska düzenlemeler saglamak için diger belirlenmis
özelliklerle birlestirilebilecegi düsünülmelidir. Tekil olarak kullanilan terimler, çogul
formlarini da ifade edebilir.
Burada açiklandigi gibi "enantiomerler" terimi, birbirinin üzerine bindirilemeyen ayna
görüntüleri olan bir stereoizomer çifti anlamina gelmektedir. Bir çift enantiyomerin
lzl karisimi "rasemik" karisim olarak adlandirilmaktadir.
Mutlak stereokimya, Cahn-lngold-Prelog RS sistemine göre belirlenmektedir. Bir
bilesik saf bir enantiyomer oldugunda, her bir kiral karbondaki stereokimya, R veya S
ile belirtilebilir. Formül Pin bilesigi, kiral bir merkeze sahiptir. Bulusun tercih edilen
düzeneginde formül I bilesigi, R ve S enantiomerleriiiin lzl rasemik karisimi
formundadir. Formül Pe ait bilesik ayrica saf R formunda veya saf S formunda veya
bunlarin herhangi bir oranda bir karisimi halinde olabilir.
Mevcut bulus, rasematlar ve formül l'e ait bilesigin optik olarak saf formlari dahil
olmak üzere tüm olasi izomerleri içermektedir. Bahsedilen formlar, kiral reaktiflerin
veya baska yöntemlerin kullanilmasi gibi bilinen geleneksel teknikler kullanilarak
hazirlanabilir.
Burada açiklandigi gibi "tuzlar" terimi, bulus bilesiginin baz ilaveli tuzlarina asit ilave
edilen hallerini ifade etmektedir. Özellikle tuzlar, bulus bilesiginin biyolojik
etkinligini ve kendi etkinligini korurken, toksisite veya herhangi bir formülasyon
zorluguna neden olan herhangi bir biyolojik veya farkli istenmeyen özelliklere sahip
olmayan tuzlari ifade eden "farmasötik olarak kabul edilebilir tuzlari" içermektedir.
Farmasötik olarak kabul edilebilir asit ilaveli tuzlar, organik asitler ve/veya inorganik
asitler ile olusturulabilir. Mevcut bulusa göre bilesigin asit ilaveli tuzlari asagidakileri
içeren bir gruptan seçilebilmektedir;asetat, aspartat, benzoat, besilat, bromür /
hidrobromür, bikarbonat / karbonat, bisülfat / sülfat, kamforsülfonat, klorür /
hidroklorür, klortheofillonat, sitrat, etabisülfonat, fumarat, gluceptat, glukonat,
glukuronat, sitrat, etabisülfat, lakodiyot, lakodiyot laktobiyonat, laurilsülfat, malat,
maleat, malonat, mandelat, mesilat, metilsülfat, naftoat, naflat, nikotinat, nitrat,
oktadekanoat, oleat, oksalat, palmitat, pamoat, fosfat / hidrojen fosfat / dihidrojen
fosfat, poligalaktu steakat sülfosalisilat, tartarat, tosilat ve trifloroasetat tuzlari.
Farmasötik olarak kabul edilebilir baz ilaveli tuzlar organik bazlar ve/Veya inorganik
bazlar ile olusturulabilir. Bulusa ait bilesigin baz ilaveli tuzlarinin hazirlanmasi için
uygun bazlar sodyum hidroksit, sodyum karbonat, sodyum bikarbonat, kalsiyum
hidroksit, kalsiyum karbonat, kalsiyum bikarbonat, magnezyum hidroksit, magnezyum
karbonat, magnezyum bikarbonat, potasyum hidroksit, potasyum karbonat, potasyum
bikarbonat ve benzerleri arasindan seçilebilir.
Burada açiklandigi gibi "izotopik olarak etiketlenmis bilesikler" terimi, bir veya daha
fazla atomun, seçilmis atomik kütle veya kütle sayisina sahip bir atom ile
degistirildigi formül I'e ait bilesikleri belirtmektedir. Bu tür degisimler, örnegin,
Bulusa ait bilesigin bu izotopik isaretli varyantlari, teknolojide bilinen saptama veya
görüntüleme teknikleri veya hastalarin radyoaktif tedavisi için kullanilabilir.
tarafindan da belirtilmis oldugu gibi insan proteininin kendisini ifade etmektedir.
MDM2 (özellikle MDM2 veya bunlarin varyantlari olarak belirtildiginde) genellikle
MDMZ, Mdm2, HDMZ, Hdm2 veya bunlarin bir varyanti adlariyla kodlanan tüm
genleri ve/veya proteinleri ifade etmektedir.
Baska bir yönünde mevcut bulus, formül I bilesigi, DRG-MDM2-5 veya bunun
farrnasötik açidan kabul gören bir türevini ve farmasötik açidan kabul gören en az bir
eksipiyan içeren farmasötik kompozisyonlar ile ilgilidir.
Bulusun tercih edilen bir düzenlemesinde, farmasötik olarak kabul edilebilir eksipiyan
asagidakileri içeren bir gruptan seçilebilmektedir; çözücüler, antioksidanlar,
koruyucular (örn. antibakteriyel ajanlar, antifungal ajanlar), izotonik ajanlar, emilim
geciktirici ajanlar, doyurucu maddeler, koruyucular, stabilizatörler, baglayicilar,
parçalayicilar, yaglayicilar, tatlandirici ajanlar, aroma ajanlari ve bunlarin
kombinasyonlari. Her bir grubun özel örnekleri Remington's Pharmaceutical Sciences,
18th Ed. Mack Printing Company, 1990 ve buna eklenen belgeler kapsaminda
verilmistir.
Formül I bilesigini içeren farmasötik bilesimler, farkli uygulama yollari için formüle
edilebilmektedir. Bulusun bir düzeneginde formül I'e ait bilesikleri ihtiva eden
farmasötik kompozisyonlar, oral uygulama, parenteral uygulama, topikal uygulama
veya rektal uygulama için formüle edilebilmektedir.
Bulusun tercih edilen bir düzenegindeki oral uygulama için bulusa ait olan farmasötik
kompozisyonlar, tabletler, pastiller, sulu veya yagli süspansiyonlar, dagilabilir tozlar
veya granüller, emülsiyon, sert veya yumusak kapsüller veya suruplar ya da iksirler
formunda olabilmektedir.
Bulusun tercih edilen bir düzeneginde parenteral uygulama için bulusa ait olan
farinasötik kompozisyonlar, izotonik çözeltiler veya süspansiyonlar formunda veya
uygulamadan önce sulandirma için uygun liyofilize toz formunda olabilmektedir.
Parenteral uygulama için bulusa ait adi geçen farmasötik kompozisyonlar,
intramüsküler, intravenöz, subkütan, intraperitoneal, intratrakeal uygulama için
kullanilabilmektedir.
Bulusun tercih edilen bir düzeneginde topikal uygulama için bulusa ait farmasötik
kompozisyonlar, sulu çözeltiler, süspansiyonlar, merhemler, macunlar, losyonlar,
transdermal yamalar, jeller, kremler veya aerosoller gibi püskürtülebilir
formülasyonlar seklinde olabilir. Bu topikal uygulama cilt, göz veya burun yoluyla
uygulamalari kapsamaktadir (yani burun içi uygulamalar). Dolayisiyla, bulusun
farmasötik bilesimleri, uygun bir iticiyle veya itici olmaksizin, basinçli kaplar, pompa,
sprey, atomizer veya nebülizör yoluyla uygulama için kuru tozlar, çözeltiler veya
aerosoller formunda olabilir.
Mevcut bulusa ait fannasötik kompozisyon veya kombinasyon, yaklasik 50-70 kg
veya yaklasik 1-500 mg veya yaklasik l-250 mg ya da yaklasik olarak bir denek için
aktif bilesen birim dozajinda olabilir. Bir bilesigin, farmasötik bilesimin veya bunlarin
kombinasyonlarinin terapötik olarak etkili dozaji, hastanin türüne, Vücut agirligina,
yasina ve bireysel durumuna, bozukluklarina veya hastaliklarina veya uygulanan
tedavi agirligina baglidir. Siradan becerilere sahip bir doktor, klinik görevlisi veya
veteriner, bozuklugun veya hastaligin ilerlemesini önlemek, tedavi etmek veya inhibe
etmek için gerekli aktif bilesenlerin her birinin etkili miktarini kolay bir sekilde
belirleyebilmektedir.
Baska bir yönden bulus, p53-MDM2 etkilesiminin rol oynadigi bir bozuklugun
tedavisinde kullanilmak üzere formül I bilesigi, DRG-MDMZ-S veya bunun
far'masötik olarak kabul edilebilir bir türevi ile ilgili olmaktadir.
Tercih edilen bir düzenekte bulus, MDM2 aktivitesinin (normal aktivite veya özellikle
asiri aktivite dahil) aracilik ettigi bir bozuklugun tedavisinde kullanilmak üzere
formül I bilesigi, DRG- MDM2-5 veya bunun farmasötik açidan kabul gören bir
türevi ile ilgili olmaktadir.
Tercih edilen bir düzenekte MDM2 aktivitesinin aracilik ettigi bozukluk, kanser gibi
proliferatif bir hastaliktir.
Bulusun bir düzeneginde kanser, iyi huylu veya kötü huylu tümörler, yumusak doku
sarkomu veya sarkom (öm. Liposarkom, rabdomiyosarkom) veya kemik kanseri (örn.
Osteosarkomlar), karsinom (örn. Beyin, böbrek, karaciger, adrenal bezi, mesane,
meme, mide, yumurtalik, kolon, rektum, prostat, pankreas, akciger, vajina veya tiroid
gibi), glioblastom, meningioma, glioma, mezotelyoma, multipl miyelom,
gastrointestinal kanser (özellikle kolon karsinomu veya kolorektal adenom), bas ve
boyun tümörü, melanoma, prostat hiperplazisi, neoplazi, epitelyal karakterli neoplazi,
akut miyeloid lösemi veya B hücresi kronik lenfositik lösemi, lenfoma (8- veya T-
hücre orij ini) ve diger organlardaki metastazlari içermektedir.
Baska bir yönden bulus, burada tanimlandigi gibi formül I'e ait bir bilesigin veya bir
tuzunun, MDMZ'nin aktivitesinin aracilik ettigi bir hastada bir bozuklugun veya
hastaligin tedavisi için ilacin üretiminde kullanimi ile ilgilidir.
Baska bir yönden bulus, formül I'e ait bir bilesigin veya bunun bir tuzunun, burada
tanimlandigi gibi, apoptoz ve/veya hücre döngüsü yavaslamasi veya durdurmasi
indükleyicileri gibi bir veya daha fazla ilave farmasötik olarak aktif maddeye
hücrelerin duyarlilastirilmasi için p53 veya bunun varyantlarini içeren hücrelerde
döngünün yavaslamasini veya tercihen durdurulmasini ve/veya apoptozu indüklemek
için kullanimi ile ilgilidir.
Baska bir yönden bulus, formül I bilesigi ve asagidakileri içeren bir gruptan seçilen
bir veya daha fazla ilave aktif madde içeren kombinasyonlar ile ilgilidir; anti-
proliferatif ajanlar, immünomodülatör ajanlar, antiviral ajanlar, antimikrobiyal ajanlar,
anti-enfektif ajanlar, anti-enflamatuar ajanlar, anestezik ajanlar, antiemetikler veya
uygun oldugunda bunlarin kombinasyonlari. Tercih edilen bir düzenekte ilave aktif
ajan, bir veya daha fazla anti-proliferatif ajandir.
Bulusun bir düzeneginde anti-proliferatif aktif ajan, asagidakileri içeren ancak
bunlarla sinirli olmayan bir gruptan seçilen bir veya daha fazla ajan
olabilir; alkilleyici ajanlar, antrasiklinler, taksanlar (sitoskeletal yikicilar), epotilonlar,
histon deasetilaz inhibitörleri, topoizomeraz I inhibitörleri, topoizomeraz II
inhibitörleri, kinaz inhibitörleri, tirozin kinaz inhibitörleri, nükleotit analoglari ve
prekürsör analoglari, peptit antibiyotikler, platinum türevleri, platinum, ve türevler
veya diger ajanlar.
Alkilleyici ajanlar asagidakileri içeren, ancak bunlarla sinirli olmayan bir gruptan
seçilebilir: bendamustin, siklofosfamid, mechlorethamine, klorainbucil, melfalan,
dakarbazin, nitrosoureler, streptozotosin, temozolomid, trabectedin.
Antrasiklinler, bunlarla sinirli olmamak üzere asagidakileri içeren bir gruptan
seçilebilir;daunorubisin, doksorubisin, epirubisin, idarubisin, mitoksantron,
valrubisin.
Taksanlar (hücre iskeleti bozuculari) asagidakileri içeren, ancak bunlarla sinirli
olmayan bir gruptan seçilebilir1pak1itaksel, dosetaksel, abraksan, taksoter,
cabazitaksel,
Epotilonlar, asagidakileri içeren, ancak bunlarla sinirli olmayan bir gruptan
seçilebilir; epotilon A, epotilon B, epotilon C, epotilon D, epotilon E, epotilon F veya
iksabepilon gibi farmasötik olarak kabul edilen bir türevi.
Histon deasetilaz inhibitörleri, asagidakileri içeren, ancak bunlarla sinirli olmayan bir
gruptan seçilebilir; belinostat, panobinostat, valproat, vorinostat, romidepsin.
Topoizomeraz I inhibitörleri, asagidakileri içeren, ancak bunlarla sinirli olmayan bir
gruptan seçilebilir; irinotekan, topotekan.
Topoizomeraz ll inhibitörleri, asagidakileri içeren, ancak bunlarla sinirli olmayan bir
gruptan seçilebilir: etoposit, teniposit, tafluposit.
Kinaz inhibitörleri, asagidakileri içeren, ancak bunlarla sinirli olmayan bir gruptan
seçilebilir; bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, Vismodegib.
Tirozin kinaz inhibitörleri, asagidakileri içeren, ancak bunlarla sinirli olmayan bir
gruptan seçilebilir; afatinib, aksitinib, bosutinib, kobimetinib, crizotinib, dasatinib,
erlotinib, gefitinib, imatinib, lapatinib, nilotinib, osimertinib, pazopanib, ruxolitinib,
sunitinib, vandetanib.
Nükleotid analoglari ve öncü analoglari, asagidakileri içeren, ancak bunlarla sinirli
olmayan bir gruptan seçilebilir; azasitidin, azatiyoprin, kladribin, klofarabin,
kapesitabin, sitarabin, doksifluridin, desitabin, floksuridin, fludarabin, florourasil (5-
FU), florourasil, gemsitabin, hidroksurea, merkapupürin, metotreksatrintaintatan,
Peptit antibiyotikler, asagidakileri içeren, ancak bunlarla sinirli olmayan bir gruptan
seçilebilir; bleomisin, aktinomisin.
Platin bazli ajanlar asagidakileri içeren ancak bunlarla sinirli olmayan bir gruptan
seçilebilir: karboplatin, cisplatin, oksaliplatin.
Retinoidler, asagidakileri içeren, ancak bunlarla sinirli olmayan bir gruptan
seçilebilir: tretinoin, alitretionoin, beksaroten, izotretinoin, tamibaroten.
Vinkaalkaloidler ve türevleri, asagidakileri içeren, ancak bunlarla sinirli olmayan bir
gruptan seçilebilir; vinblastin, vinkristin, Vinflunin, vinorelbin.
Diger ajanlar asagidakileri içeren ancak bunlarla sinirli olmayan bir gruptan
seçilebilir: metotreksat, pemetrexed, pralatrexed, raltitrexed, etoposide teniposid,
abirateron, bicalutamide, siproteron, degarelix, exemestane, fulvestrant, goserelin,
histrelin, leuprolid, mifepriston, triptorelin, lenalidomid, pomalidomid, talidomid,
everolimus, temsirolimus, anagrelid, ceritinib, dabrafenib, idelalisib, ibrutinib,
palbociclib, vemurafenib, bleomisin, daktinomisin, eribülin, estramustin, ixabepilone,
mitomisin, prokarbazin, alektinib, tluxymesterone, iobenguane, imiguimod, interferon,
ixazomib, lanreotid, lentinan, oktreotid, omasetaksin, tegafur, gimerazil, oterasil, urasil,
combretastatin.
Bulusun bir düzeneginde bu gibi kombinasyonlar, formül I'e ait bilesigin ve bir veya
daha fazla terapötik açidan aktif ajanm, tercihen anti-proliferatif ajanlarin birlikte
formüle edildigi bir formda olabilir.
Bulusun baska bir düzeneginde formül I'e ait bilesik ve bir veya daha fazla terapötik
açidan aktif ajan, tercihen anti-proliferatif ajanlar ayri ayri formüle edilir ancak buna
ihtiyaç duyan bir hastaya ayni anda veya sirayla uygulanir.
Mevcut özellikler kapsaminda içerme anlami da dahil edilebilmektedir.
Teknik olarak uygun olan yerlerde, bulusa iliskin düzenlemeler birlestirilebilir.
Burada, düzenlemelerin belirli özellikler/elemanlar içerdigi belirtilmektedir. Açiklama
ayrica temel olarak adi geçen özelliklerden/elemanlardan olusan ayri uygulamalara da
uzanmaktadir.
Patentler ve basvurular gibi teknik referanslar, isbu belgeye referans olarak dahil
edilmistir.
Burada spesifik olarak ve açikça belirtilen herhangibir düzenleme, tek basina veya bir
veya daha fazla baska düzenleme ile kombinasyon halinde bir feragatnamenin
temelini olusturabilmektedir.
Bulus su anda yalnizca açiklayici olan ve hiçbir sekilde asagidakilerin kapsamini
sinirlayiei olarak yorumlanmamasi gereken, asagidaki örneklere referans verilmek
suretiyle tanimlanacaktir.
ÖRNEKLER
Örnek 1: Hücre Kültürü Deneyleri
HCT 116 kolon kanseri ve MDA-MB231 meme kanseri hücre dizileri hücre kültürü
deneylerinde kullanilir.
Hücreler, %10 PES (Gibco) ve 1)( penisilin/streptomisin (Multicell) ile takviye
edilmis yüksek glikozlu DMEM ortami (Biosera) ile tedavi edilmistir. Deney,
inhibitörlere maruz birakilmasindan önce 24 oyuklu hücre kültür plakalarinin her bir
oyugu için 10.000 hücre içerecek sekilde tasarlanmistir.
Formül I'e ait bilesik, 20 mM stok olarak DMSO ile çözündürülmüstür. 24 saat sonra
çözelti, %10 PES ile DMEM içerisinde seyreltilmis ve nihai araç DMSO
konsantrasyonu, maksimum %05 olmustur. Bu nedenle, araç grubu deneylerde %0.5
DMSO konsantrasyon içermistir. Hücrelerin yogun bir sekilde kültive edilmesi,
çogalma kapasitesinde bir azalmaya neden olur. Bu nedenle hücre doluluk orani,
MTT hücre canliligi deneyi yari-maksimal inhibisyon konsantrasyonunun degerlerini
tespit etmek için kullanilmistir (IC50). 10":) ila 10`4M arasinda degisen formül l
bilesiginin farkli konsantrasyonlari, tek doz tedavi ile MDA-MB231 hücre çizgileri
üzerinde test edildi. 570 nm absorbans degerleri kaydedilmis ve IC50 degerleri, doz
yanitlari - Graphpad Prism 8 yazilimi inhibisyon egrileri ve dogrusal olmayan
regresyon analizi kullanilarak hesaplanmistir. Formül 1 bilesiginin IC50 degerinin 98
uM (Sekil 1) oldugu belirlenmistir.
Örnek 2: Hücre Çogalmasi Inhibisyon Analizi
Proliferasyon inhibisyon analizi için, hücreler, 1 x 104 hücre/oyuklu hücre içerisinde
24 plaka ile gece boyunca ilaç tedavisi olmaksizin tohumlanmistir. Hücre çogalma
deneyleri sirasinda, her hücre hattinda bes günlük tedavi gerçeklestirilmis ve her bir
deneyi kontrol etmek için deneyler üç kez tekrarlanmistir. Üçüncü günden sonra hücre
canliliginda anlamli bir fark gözlenmemistir. Bu nedenle, farkli ilaç
konsantrasyonlarina sahip hücreler iki gün boyunca tedavi edilmistir. 48 saat sonra
hücrelere MTT uygulanmis ve 37°C'de 4 saat inkübe edilmistir, formazan DMSO
(Sigma-Aldrich, St. Louis, ABD) ile çözündürülmüs ve absorbans, 570 nm'de
ölçülmüstür.
MTT hücresi çogalma tahlil sonuçlari Sekil 2'de gösterilmektedir. Molekül
konsantrasyonu 100 uM olmus ve daha düsük konsantrasyonlar gösterilmemistir.
Araç, sadece %0,5 DMSO ile tedavi edilen gruplari temsil eder ve islem yapilmamis
hiçbir molekül, islem yapilmis gruplari temsil etmemektedir. Molekül yanitlari, 12
saat, 24 saat, 48 saat ve 72 saatte MTT tedavisi üzerine hücrelerin spektrofotometrik
analizi ile elde edilen hücre yasayabilirligi ile degerlendirilmistir. Molekül gruplari,
tasit ve tedavi edilmemis gruplara göre istatistiksel olarak anlamli farklilik
göstermistir. Gratiklerdeki istatistiksel anlamlilik, ANOVA testi kullanilarak her bir
tedavi grubunun DMSO kontrolü ile karsilastirilmasiyla belirlenmis ve anlamlilik p
<0.001 olarak kabul edilmistir (Sekil 2).
Formüll
0.6 R(=Ü.65
°I3I I I I I
-10 -8 -6 -4 -2
log (Konsantrasyon)
Formüll
2.0**
Absorbans + UNT
1-5-1 I DMSO
/r' . A Formüll
1.0- 1/ V
0.54 fî_ .i ”
Süre (Saat)
Claims (8)
1. DRG-MDMZ-S olan formül I ile gösterilen bir bilesik veya bunun fannasötik 5 olarak kabul edilebilir bir türevi.
Formül I2. Formül l'e ait farmasötik açidan kabul edilebilir türev, hidratlari, solvatlari, ön ilaçlari, tüm stereoizomerleri, tuzlari, esterleri, totomerleri, izotopik olarak etiketlenmis türevleri veya insan vücudunun fizyoloj ik kosullari altinda olusan formül I'e ait bilesik formlari seklinde olabilecek, Istem l'e göre bir bilesik. 20 3. F orrnül la ile gösterilmis oldugu gibi formül I bilesiginin farmasötik olarak kabul edilebilir türevi olabilecek, Istem 2'ye göre bir bilesik.
F ormül la
4. Bilesigin, R ve S enantiomerlerinin lil rasemik karisimi formunda oldugu Istem 1-3'e göre bir bilesik.
5. p53- MDM2 etkilesiminin rol oynadigi bir bozuklugun tedavisinde kullanilmak üzere Istem l-4'e göre bir bilesik. 30
6. Rahatsizligm proliferatif bir hastalik oldugu Istem 5'te istenen kullanim için bir bilesik.
7. Proliferatif rahatsizligin kanser oldugu, Istem 6'da istendigi gibi kullanim için bir bilesik. 35
8. Kanserin, iyi huylu veya kötü huylu tümörler, yumusak doku sarkomu veya sarkom (öm. Liposarkom, rabdomiyosarkom) veya kemik kanseri (öm. Osteosarkomlar), karsinom (örn. Beyin, böbrek, karaciger, adrenal bezi, mesane, meme, mide, yumurtalik, kolon, rektum, prostat, pankreas, akciger, vajina veya tiroid gibi), glioblastom, meningioma, glioma, mezotelyoma, multipl miyelom, gastrointestinal kanser (özellikle kolon karsinomu veya kolorektal adenom), bas ve boyun tümörü, melanoma, prostat hiperplazisi, neoplazi, epitelyal karakterli neoplazi, akut miyeloid lösemi veya B hücresi kronik lenfositik lösemi, lenfoma (B- veya T- hücre orijini) ve diger organlardaki metastazlari içermekte oldugu Istem 7'de istendigi gibi kullanim için bir bilesik. . Bir veya daha fazla ilave farmasötik aktif` ajan ile kombinasyon halinde kullanilmak üzere Istem l-4'e göre bir bilesik. Farmasötik olarak aktif' ilave ajanin, anti-proliferatif ajanlar, immünomodülatör ajanlar, antiviral ajanlar, antimikrobiyal ajanlar, anti-enfektif ajanlar, anestezik ajanlar, antiemetikler veya bunlarin kombinasyonlarini içeren bir gruptan seçildigi Istem 9'da istenen kullanim için bir bilesik. Antipoliferatif aj anlarin, antrasiklinler, taksanlar (sitoskeletal yikicilar), epotilonlar, histon deasetilaz inhibitörleri, topoizomeraz l inhibitörleri, topoizomeraz ll inhibitörleri, kinaz inhibitörleri, tirozin kinaz kinazlari içeren bir gruptan seçilir. inhibitörler, nükleotid analoglari ve öncü analoglari, peptit antibiyotikleri, platin bazli ajanlar, retinoidler, Vinka alkaloidleri ve türevleri veya diger ajanlar arasindan seçildigi Istem 10'da istenen kullanim için bir bilesik. Istem 1-4'e göre bir bilesikten ve en az bir farmasötik olarak kabul edilebilir eksipiyan içeren farmasötik bir kompozisyondan meydana gelen bilesik. Istem l-4'e göre bir bilesik ve anti-proliferatif ajanlar, immünomodülatör ajanlar, antiviral ajanlar, antimikrobiyal ajanlar, anti-enfektif ajanlar, anestezik ajanlar, antiemetikler veya kombinasyonlar içeren bir gruptan seçilen bir veya daha fazla ilave farmasötik aktif ajan içeren farmasötik bir kompozisyon içeren bilesik.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2020/02326A TR202002326A2 (tr) | 2020-02-17 | 2020-02-17 | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-5 |
US17/904,404 US20230063449A1 (en) | 2020-02-17 | 2021-02-17 | Drg-mdm2-5 for use as a novel mouse double minute 2 (mdm2) inhibitor |
PCT/TR2021/050147 WO2021167574A1 (en) | 2020-02-17 | 2021-02-17 | Drg-mdm2-5 for use as a novel mouse double minute 2 (mdm2) inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2020/02326A TR202002326A2 (tr) | 2020-02-17 | 2020-02-17 | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-5 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR202002326A2 true TR202002326A2 (tr) | 2021-08-23 |
Family
ID=77391557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2020/02326A TR202002326A2 (tr) | 2020-02-17 | 2020-02-17 | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-5 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230063449A1 (tr) |
TR (1) | TR202002326A2 (tr) |
WO (1) | WO2021167574A1 (tr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1768954A4 (en) * | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS |
-
2020
- 2020-02-17 TR TR2020/02326A patent/TR202002326A2/tr unknown
-
2021
- 2021-02-17 WO PCT/TR2021/050147 patent/WO2021167574A1/en active Application Filing
- 2021-02-17 US US17/904,404 patent/US20230063449A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021167574A1 (en) | 2021-08-26 |
US20230063449A1 (en) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tomaselli et al. | Epigenetic polypharmacology: A new frontier for epi‐drug discovery | |
KR102666477B1 (ko) | 글루타민 유사체의 프로드럭 | |
CN106860870B (zh) | 抗肿瘤生物碱的联合治疗 | |
BR112017017009B1 (pt) | Composição farmacêutica | |
JP2018529713A (ja) | Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法 | |
AU2009221120A1 (en) | Improved antitumoral treatments | |
AU2013202507B2 (en) | Inhibition of drug resistant cancer cells | |
EP3034076A1 (en) | Combined application of isothiocyanate compound and anti-cancer medicine | |
BG107281A (bg) | Комбиниран химиотерапевтичен състав | |
EP2457572A1 (en) | Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases | |
TR202002326A2 (tr) | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-5 | |
US20230090414A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
US20230098888A1 (en) | Drg-mdm2-6 for use as a novel mouse double minute 2 (mdm2) inhibitor | |
US20230073261A1 (en) | Drg-mdm2-1 for use as a novel mouse double minute 2 (mdm2) inhibitor | |
US20230067644A1 (en) | Drg-mdm2-3 for use as a novel mouse double minute 2 (mdm2) inhibitor | |
TR202002325A2 (tr) | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4 | |
TR202002323A2 (tr) | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak | |
CN113164437A (zh) | 要用作组合药物的含有ezh1/2双重抑制剂的药物组合物 | |
US20230088086A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
US20230074698A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
US20230099876A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
US20230109522A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
AU2012312308B2 (en) | Romidepsin and 5-azacitidine for use in treating lymphoma | |
NZ622752B2 (en) | Romidepsin and 5 - azacitidine for use in treating lymphoma |